Yanan Zhu
Stock Analyst at Wells Fargo
(2.95)
# 1,395
Out of 5,141 analysts
90
Total ratings
38.67%
Success rate
2.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Overweight | $40 → $50 | $43.21 | +15.71% | 3 | Feb 20, 2026 | |
| RAPT RAPT Therapeutics | Downgrades: Equal-Weight | $58 | $57.92 | +0.14% | 8 | Jan 20, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $8 → $11 | $4.70 | +134.04% | 4 | Jan 5, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $100 | $83.15 | +20.26% | 4 | Jan 5, 2026 | |
| QURE uniQure | Maintains: Overweight | $80 → $60 | $23.43 | +156.08% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $17 → $12 | $12.64 | -5.06% | 7 | Nov 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $50 → $45 | $18.88 | +138.35% | 7 | Nov 5, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $7.67 | +160.76% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $1.79 | +123.46% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $35.58 | +26.48% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $1.46 | +721.92% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.46 | +71.23% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.67 | +199.40% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $2.87 | +387.80% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $72.86 | +2.94% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $27.59 | +153.72% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.49 | +186.53% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $53.46 | +21.59% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $10.40 | +188.46% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.38 | +939.50% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.72 | +16,444.12% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $844.41 | -61.39% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.34 | +576.98% | 2 | Oct 29, 2020 |
Spyre Therapeutics
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $50
Current: $43.21
Upside: +15.71%
RAPT Therapeutics
Jan 20, 2026
Downgrades: Equal-Weight
Price Target: $58
Current: $57.92
Upside: +0.14%
Taysha Gene Therapies
Jan 5, 2026
Maintains: Overweight
Price Target: $8 → $11
Current: $4.70
Upside: +134.04%
Ionis Pharmaceuticals
Jan 5, 2026
Maintains: Overweight
Price Target: $82 → $100
Current: $83.15
Upside: +20.26%
uniQure
Nov 12, 2025
Maintains: Overweight
Price Target: $80 → $60
Current: $23.43
Upside: +156.08%
Intellia Therapeutics
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $17 → $12
Current: $12.64
Upside: -5.06%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $18.88
Upside: +138.35%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $7.67
Upside: +160.76%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $1.79
Upside: +123.46%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $35.58
Upside: +26.48%
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.46
Upside: +721.92%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.46
Upside: +71.23%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.67
Upside: +199.40%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.87
Upside: +387.80%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $72.86
Upside: +2.94%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $27.59
Upside: +153.72%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.49
Upside: +186.53%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $53.46
Upside: +21.59%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $10.40
Upside: +188.46%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.38
Upside: +939.50%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.72
Upside: +16,444.12%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $844.41
Upside: -61.39%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.34
Upside: +576.98%